arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
November 04, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update
October 31, 2024 07:30 ET | Kymera Therapeutics, Inc.
KT-621 (STAT6) IND cleared by FDA and dosing in the Phase 1 clinical trial initiated, with data expected in the first half of 2025 Sanofi expanding KT-474/SAR444656 (IRAK4) Phase 2 clinical trials in...
arvinas_logoART_lg.jpg
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
October 30, 2024 07:00 ET | Arvinas Inc.
– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases
October 24, 2024 07:00 ET | Kymera Therapeutics, Inc.
KT-621, an oral degrader, is the first STAT6 targeted medicine to enter clinical development, with the potential to address multiple immuno-inflammatory diseases KT-621 has demonstrated...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31
October 23, 2024 07:15 ET | Kymera Therapeutics, Inc.
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
October 23, 2024 07:00 ET | Kymera Therapeutics, Inc.
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using...
arvinas_logoART_lg.jpg
Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day
October 22, 2024 16:05 ET | Arvinas Inc.
NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024
October 21, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Announces FDA Clearance of Investigational New Drug Application for KT-621, a First-in-Class, Oral STAT6 Degrader
October 09, 2024 07:00 ET | Kymera Therapeutics, Inc.
KT-621 has demonstrated dupilumab-like activity and was well tolerated ina wide variety of preclinical models of TH2 diseases KT-621 is expected to start Phase 1 in October, with Phase 1 data in...
Nurix.png
Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology
October 09, 2024 07:00 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat...